Lytix Biopharma AS (STU:6BG) Total Equity: €10.25 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:6BG Lytix Biopharma AS STU:6BG
31 GF Score
Price €0.80
GF Value €0.02
! 2 Warning Signs
View Full Analysis

What is Lytix Biopharma AS Total Equity?

Lytix Biopharma AS STU:6BG -3.37% 31 Total Equity is €10.25 Mil as of Mar. 2026. GuruFocus rates STU:6BG with a GF Score™ of 31/100 and a GF Value™ of €0.02. The stock has 2 warning signs investors should review.

Lytix Biopharma AS's total equity for the quarter that ended in Mar. 2026 was €10.25 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Lytix Biopharma AS Total Equity Historical Data

* Premium members only.

The historical data trend for Lytix Biopharma AS's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lytix Biopharma AS Total Equity Chart

Lytix Biopharma AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 18.69 12.90 4.46 9.18 5.22

Lytix Biopharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.24 7.77 6.72 5.22 10.25
STU:6BG
31GF Score
Lytix Biopharma AS STU:6BG
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lytix Biopharma AS Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Lytix Biopharma AS's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=6.889-1.671
=5.22

Lytix Biopharma AS's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=11.535-1.285
=10.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €10.25 Mil mean?
Lytix Biopharma AS (STU:6BG) has a Total Equity of €10.25 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Lytix Biopharma AS and its competitors.
Is Lytix Biopharma AS's Total Equity too high?
Lytix Biopharma AS's current Total Equity is €10.25 Mil. Overall, Lytix Biopharma AS has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Lytix Biopharma AS's Total Equity compare to VRTX and REGN?
Lytix Biopharma AS's Total Equity of €10.25 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Lytix Biopharma AS and its competitors. Lytix Biopharma AS's current Total Equity is €10.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lytix Biopharma AS stock overvalued right now?
Lytix Biopharma AS (STU:6BG) has a current Total Equity of €10.25 Mil. The stock's GF Value™ is €0.02, compared to a current price of €0.80 — trading 3910% above its estimated fair value. The current Total Equity is €10.25 Mil. Lytix Biopharma AS's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Lytix Biopharma AS (STU:6BG), the current Total Equity is €10.25 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lytix Biopharma AS (STU:6BG) Overvalued in 2026?

Based on GuruFocus' analysis, Lytix Biopharma AS stock appears to be overvalued. The current stock price of €0.80 is trading 3910% above its estimated GF Value™ of €0.02.

Key valuation signals for STU:6BG:

  • Total Equity: €10.25 Mil
  • GF Value™: €0.02 vs. price of €0.80 (3910% above fair value)
  • GF Score™: 31/100 with 2 warning signs

No single metric tells the full story. See the STU:6BG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lytix Biopharma AS Business Description

Other Exchanges LYTIX:Norway
Address Sandakerveien 138, Oslo, NOR, 0484
Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. The company's technology platform is designed to convert immunologically "cold" tumors into "hot" tumors by releasing tumor antigens and activating tumor-specific immune responses. The product pipeline of the company includes LTX-401 and LTX-315. The company operates in Norway and the USA, majority of revenue is from the USA.
31GF Score

Get the complete analysis for STU:6BG

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.80
Price
€0.02
GF Value